Cancers & treatments·Regimen libraryFirst line

Dabrafenib + trametinib

Checked 2026-09-09

BRAF V600-mutant melanoma (adjuvant 1 year or metastatic), NSCLC, anaplastic thyroid cancer and tumour-agnostic use

One cycle

every 28 days

28-day cycle, until progression; 12 months adjuvantOral Daily oral course

Components

Drug	Dose	Route	Days	Note
Dabrafenib Small-molecule kinase inhibitors (BRAF + MEK)	150 mg twice daily	Oral	D1-28
Trametinib Small-molecule kinase inhibitors (BRAF + MEK)	2 mg once daily	Oral	D1-28

Cycles

until progression; 12 months adjuvant

28-day cycle

Emetogenicity

Low (10-30%)

G-CSF

Not routine

Notes

Pyrexia in over half of patients: interrupt both drugs at the first fever.
Dabrafenib induces CYP3A4 and CYP2C9: hormonal contraception may fail.

Used in

Melanoma Non-small-cell lung cancer Thyroid cancer Glioma & glioblastoma

Trials

COMBI-AD ROAR (anaplastic thyroid cancer cohort)

Products

Dabrafenib + trametinib

Source

COMBI-d, NEJM 2014; COMBI-AD, NEJM 2017

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.